US5219837A
(en)
|
1990-06-21 |
1993-06-15 |
Trustees Of The University Of Pennsylvania |
Method of stimulating myelination of cells
|
US5858725A
(en)
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US5843749A
(en)
|
1991-07-26 |
1998-12-01 |
Regeneron Pharmaceuticals, Inc. |
Ehk and Ror tyrosine kinases
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
US7473423B2
(en)
|
1994-04-29 |
2009-01-06 |
Mayo Foundation For Medical Education And Research |
Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
|
ES2292173T3
(es)
|
1994-12-30 |
2008-03-01 |
Planet Biotechnology, Inc. |
Procedimiento para producir inmunoglobulinas que contienen proteinas de proteccion en plantas y sus usos.
|
JP4423680B2
(ja)
|
1995-06-07 |
2010-03-03 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
Cdr−グラフト化抗組織因子抗体及びその使用
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
WO1998041541A1
(fr)
|
1997-03-19 |
1998-09-24 |
Johns Hopkins University |
Utilisations therapeutiques de molecules de proteines grip et apparentees a grip
|
DK1032660T3
(da)
|
1997-11-17 |
2010-01-18 |
Micromet Ag |
Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop
|
PL343322A1
(en)
|
1998-04-03 |
2001-08-13 |
Chugai Pharmaceutical Co Ltd |
Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
|
US6605709B1
(en)
|
1999-04-09 |
2003-08-12 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
|
EP1267926A2
(fr)
|
2000-03-17 |
2003-01-02 |
Millennium Pharmaceuticals, Inc. |
Methode d'inhibition de la stenose et de la restenose
|
PT2281843T
(pt)
|
2000-06-16 |
2017-01-02 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7214786B2
(en)
|
2000-12-14 |
2007-05-08 |
Kovalic David K |
Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
|
US20140072980A1
(en)
|
2001-01-16 |
2014-03-13 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
US20140072979A1
(en)
|
2001-01-16 |
2014-03-13 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
AU2002245272B2
(en)
|
2001-01-16 |
2006-06-29 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
JP2004538324A
(ja)
|
2001-08-03 |
2004-12-24 |
メディカル リサーチ カウンシル |
細胞内抗体
|
ES2466377T3
(es)
|
2001-08-23 |
2014-06-10 |
Rsr Limited |
Regiones epitópicas de un receptor de tirotropina (TSH), usos de las mismas y anticuerpos para las mismas
|
US7226594B2
(en)
|
2001-11-07 |
2007-06-05 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
JP4063769B2
(ja)
|
2001-12-28 |
2008-03-19 |
中外製薬株式会社 |
タンパク質安定化方法
|
ATE509032T1
(de)
|
2002-02-13 |
2011-05-15 |
Ludwig Inst For Cancer Res Ltd |
Chimerizierte gm-csf antikörper
|
US7314974B2
(en)
|
2002-02-21 |
2008-01-01 |
Monsanto Technology, Llc |
Expression of microbial proteins in plants for production of plants with improved properties
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
US20060234226A1
(en)
|
2002-04-26 |
2006-10-19 |
Fahner Robert L |
Non-affinity purification of proteins
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
EP1544291A4
(fr)
|
2002-07-19 |
2006-08-02 |
Towa Kagaku Co Ltd |
Nouveau procede de production d'une enzyme d'anticorps, nouvelle enzyme d'anticorps et utilisation correspondante
|
EP2298806A1
(fr)
|
2002-10-16 |
2011-03-23 |
Purdue Pharma L.P. |
Anticorps se fixant sur des polypeptides CA 125/0722P associés à des cellules et leurs procédés d'utilisation
|
CA2515081A1
(fr)
|
2003-02-07 |
2004-08-19 |
Protein Design Labs, Inc. |
Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
NZ543202A
(en)
|
2003-05-31 |
2008-04-30 |
Micromet Ag |
Pharmaceutical composition comprising a bispecific antibody for epcam
|
US7569389B2
(en)
|
2004-09-30 |
2009-08-04 |
Ceres, Inc. |
Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
DK1673398T3
(da)
|
2003-10-16 |
2011-04-18 |
Micromet Ag |
Multispecifikke, deimmuniserede CD3-bindere
|
US7612179B2
(en)
|
2003-11-28 |
2009-11-03 |
Astrazeneca Ab |
antibodies binding to a C-terminal fragment of apoliopoprotein E
|
KR20130133302A
(ko)
|
2003-12-10 |
2013-12-06 |
메다렉스, 인코포레이티드 |
Ip―10 항체 및 그의 용도
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
WO2005070966A2
(fr)
|
2004-01-16 |
2005-08-04 |
Regeneron Pharmaceuticals, Inc. |
Polypeptides hybrides capables d'activer des recepteurs
|
SI1716178T1
(sl)
|
2004-02-16 |
2010-11-30 |
Micromet Ag |
Manj imunogene vezne molekule
|
EP3653641A1
(fr)
|
2004-02-19 |
2020-05-20 |
Genentech, Inc. |
Anticorps à regions hypervariables réparées
|
US7504086B2
(en)
|
2004-03-31 |
2009-03-17 |
Canon Kabushiki Kaisha |
Structure and method for releasing substance therefrom
|
WO2005100605A1
(fr)
|
2004-04-06 |
2005-10-27 |
The Regents Of The University Of California |
Recepteur a activite tyrosine kinase orphelin en tant que cible dans le cancer du sein
|
US7625561B2
(en)
|
2004-04-22 |
2009-12-01 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Diabody which specifically binds Streptococcus surface antigen I/II and methods of use thereof
|
JPWO2005105998A1
(ja)
|
2004-04-27 |
2008-07-31 |
財団法人化学及血清療法研究所 |
ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
|
UY28886A1
(es)
|
2004-05-10 |
2005-12-30 |
Boehringer Ingelheim Int |
Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
|
WO2005123777A2
(fr)
|
2004-06-09 |
2005-12-29 |
Genentech, Inc. |
Procede de traitement du granulome annulaire ou sarcoide
|
EP1778845A2
(fr)
|
2004-08-16 |
2007-05-02 |
CropDesign N.V. |
Plantes possedant des caracteristiques de croissance ameliorees et leur methode de fabrication
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
AU2005291486A1
(en)
|
2004-10-01 |
2006-04-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Novel antibodies directed to the mammalian EAG1 ion channel protein
|
WO2006067122A2
(fr)
|
2004-12-20 |
2006-06-29 |
Crucell Holland B.V. |
Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
|
PT1848744E
(pt)
|
2005-01-27 |
2012-04-24 |
Novimmune Sa |
Anticorpos anti-interferão gama e os seus processos de utilização
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
BRPI0609543B1
(pt)
|
2005-03-31 |
2021-11-09 |
Biomedics Inc |
Anticorpo monoclonal anti-cd20, hibridoma, anticorpo monoclonal anti-cd20 quimérico, anticorpo monoclonal anti-cd20 humanizado, agente de diagnóstico, e, agente terapêutico
|
JP5004154B2
(ja)
|
2005-04-06 |
2012-08-22 |
一般財団法人化学及血清療法研究所 |
組換え抗ボツリヌス神経毒素抗体
|
PL1874818T3
(pl)
|
2005-04-22 |
2011-09-30 |
Lilly Co Eli |
Przeciwciała swoiste wobec TGF-beta 1
|
EP1882392A4
(fr)
|
2005-05-10 |
2009-07-01 |
Monsanto Technology Llc |
Genes et leurs utilisations pour l'ameliorations de plantes
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
SG10201402712QA
(en)
|
2005-08-31 |
2014-08-28 |
Merck Sharp & Dohme |
Engineered anti-il-23 antibodies
|
EP1948680A4
(fr)
|
2005-10-28 |
2010-01-13 |
Univ California |
Methodes et composes de detection et d'isolement de cellules lymphomatiques
|
WO2008103849A2
(fr)
|
2007-02-21 |
2008-08-28 |
The Regents Of The University Of California |
Méthodes et composés pour la détection et l'isolement de cellules de lymphomes
|
CA2627075A1
(fr)
|
2005-11-14 |
2007-05-18 |
Bioren, Inc. |
Ultra-humanisation d'anticorps par production et analyse de librairies cdr matures predites de type blast et cohorte
|
USRE45660E1
(en)
|
2006-02-14 |
2015-09-01 |
Bp Corporation North America Inc. |
Xylanases, nucleic acids encoding them and methods for making and using them
|
JPWO2007102200A1
(ja)
|
2006-03-07 |
2009-07-23 |
国立大学法人大阪大学 |
抗cd20モノクローナル抗体
|
WO2007146957A2
(fr)
|
2006-06-13 |
2007-12-21 |
Irm Llc |
Procédés et compositions destinés au traitement du cancer
|
WO2008021290A2
(fr)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Protéines spécifiques d'organes et procédés d'utilisation
|
ES2444065T3
(es)
|
2006-08-18 |
2014-02-24 |
Novartis Ag |
Anticuerpo específico para PRLR y usos del mismo
|
CA2664738C
(fr)
|
2006-09-29 |
2017-03-07 |
Oncomed Pharmaceuticals, Inc. |
Compositions et procedes permettant de diagnostiquer et de traiter le cancer
|
US7718774B2
(en)
|
2006-11-08 |
2010-05-18 |
Macrogenics, Inc. |
TES7 and antibodies that bind thereto
|
FR2909092B1
(fr)
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
WO2008076868A2
(fr)
|
2006-12-18 |
2008-06-26 |
Abbott Laboratories |
Méthodes et compositions associées à la modulation du récepteur tyrosine kinase orphelin de type 1 (ror-1)
|
AR064610A1
(es)
|
2006-12-22 |
2009-04-15 |
Schering Corp |
Anticuerpos contra el cd200r
|
US8298545B2
(en)
|
2007-02-07 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
US9745367B2
(en)
|
2007-03-23 |
2017-08-29 |
Novelmed Theraputics, Inc. |
Alternative pathway specific antibodies for treating arthritis
|
WO2008127735A1
(fr)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Conjugués d'anticorps il3ralpha et leurs utilisations
|
EP2142640B1
(fr)
|
2007-05-03 |
2012-01-04 |
Regeneron Pharmaceuticals, Inc. |
Identification de cellules souches embryonnaires à compétence germinale
|
US8318163B2
(en)
|
2007-05-17 |
2012-11-27 |
Genentech, Inc. |
Anti-pan neuropilin antibody and binding fragments thereof
|
CN101687924A
(zh)
|
2007-07-04 |
2010-03-31 |
株式会社未来创药研究所 |
抗Muc17抗体
|
US8299318B2
(en)
|
2007-07-05 |
2012-10-30 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
AU2008278803A1
(en)
|
2007-07-25 |
2009-01-29 |
Astrazeneca Ab |
Targeted binging agents directed to KDR and uses thereof - 035
|
CN101848999A
(zh)
|
2007-09-06 |
2010-09-29 |
国立大学法人大阪大学 |
抗-cd20单克隆抗体
|
US8362325B2
(en)
|
2007-10-03 |
2013-01-29 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
US7968687B2
(en)
|
2007-10-19 |
2011-06-28 |
Seattle Genetics, Inc. |
CD19 binding agents and uses thereof
|
EP3211011A1
(fr)
|
2007-11-16 |
2017-08-30 |
Nuvelo, Inc. |
Anticorps pour lrp6
|
DK2236604T3
(en)
|
2007-12-05 |
2016-10-03 |
Chugai Pharmaceutical Co Ltd |
The anti-NR10 antibody and use thereof
|
PT2851374T
(pt)
|
2007-12-14 |
2017-06-20 |
Pfizer |
Moléculas de ligação ao recetor humano ox40
|
CA2707637A1
(fr)
|
2007-12-17 |
2009-06-25 |
Dyax Corp. |
Compositions et procedes pour traiter des troubles osteolytiques comprenant des proteines de liaison a mmp-14
|
CA2709354C
(fr)
|
2007-12-21 |
2014-06-17 |
Amgen Inc. |
Anticorps anti-amyloide et utilisations de ceux-ci
|
JP5690593B2
(ja)
|
2007-12-26 |
2015-03-25 |
ヴァクシネックス, インコーポレイテッド |
抗c35抗体併用療法および方法
|
US8603474B2
(en)
|
2008-01-29 |
2013-12-10 |
Ludwig Institute For Cancer Research, Ltd. |
Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
|
US9029636B2
(en)
|
2008-02-05 |
2015-05-12 |
Monsanto Technology Llc |
Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
WO2009101611A1
(fr)
|
2008-02-11 |
2009-08-20 |
Curetech Ltd. |
Anticorps monoclonaux pour le traitement de tumeurs
|
JP2011517662A
(ja)
|
2008-03-03 |
2011-06-16 |
ダイアックス コーポレーション |
メタロプロテアーゼ9結合タンパク質
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
CA2720614A1
(fr)
|
2008-04-07 |
2009-10-15 |
Kalobios Pharmaceuticals, Inc. |
Neutralisation de gm-csf pour le traitement d'une insuffisance cardiaque
|
EP2280997A2
(fr)
|
2008-04-18 |
2011-02-09 |
Xencor, Inc. |
Anticorps monoclonaux d équivalent humain conçus à partir de régions variables non humaines
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US8410251B2
(en)
|
2008-06-20 |
2013-04-02 |
National University Corporation Okayama University |
Antibody against calcified globule and use of the same
|
EP2313435A4
(fr)
|
2008-07-01 |
2012-08-08 |
Aveo Pharmaceuticals Inc |
Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
|
MX2011000071A
(es)
|
2008-07-02 |
2011-05-03 |
Emergent Product Dev Seattle |
Inmunoterapeuticos de interleucina-6 (il6).
|
MX2011000543A
(es)
|
2008-07-16 |
2011-04-27 |
Inst Research In Biomedicine |
Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
|
US8710022B2
(en)
|
2008-07-18 |
2014-04-29 |
National University Corporation Nagoya University |
Cell proliferation inhibitor
|
MX2011000778A
(es)
|
2008-07-31 |
2011-03-15 |
Basf Plant Science Gmbh |
Plantas con caracteristicas modificadas de crecimiento y un metodo para obtenerlas.
|
US8399630B2
(en)
|
2008-08-20 |
2013-03-19 |
Centocor Ortho Biotech Inc. |
Engineered anti-IL-13 antibodies, compositions, methods and uses
|
CA3050455A1
(fr)
|
2008-11-03 |
2010-06-03 |
Adc Therapeutics Sa |
Anticorps qui bloquent specifiquement l'activite biologique d'un antigene tumoral
|
US8183346B2
(en)
|
2008-12-05 |
2012-05-22 |
Eli Lilly And Company |
Anti-ferroportin 1 monoclonal antibodies and uses thereof
|
WO2010083179A2
(fr)
|
2009-01-16 |
2010-07-22 |
Monsanto Technology Llc |
Nouvelles molécules de protéine et d'acide nucléique isolées obtenues à partir de soja et procédés d'utilisation desdites molécules pour générer des plantes transgéniques présentant des caractéristiques agronomiques améliorées
|
US8673307B1
(en)
|
2009-03-09 |
2014-03-18 |
The Rockefeller University |
HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
|
CN102388068B
(zh)
|
2009-03-20 |
2015-05-20 |
安姆根有限公司 |
α-4-β-7异二聚体特异性拮抗剂抗体
|
RU2542394C2
(ru)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Гуманизированные антитела против light и их применение
|
HUE025726T2
(en)
|
2009-03-25 |
2016-04-28 |
Genentech Inc |
Anti-FGFR3 antibodies and their use
|
WO2010117455A2
(fr)
|
2009-04-08 |
2010-10-14 |
U.S. Army Medical Research Institute Of Infectious Diseases |
Anticorps monoclonaux humains protecteurs contre la peste bubonique
|
DK2419447T3
(en)
|
2009-04-17 |
2017-09-25 |
Immunas Pharma Inc |
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
|
WO2010124188A1
(fr)
|
2009-04-23 |
2010-10-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps anti-ror1 humain
|
WO2010129304A2
(fr)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Procédé de fabrication de molécules hétéromultimères
|
EA023179B1
(ru)
|
2009-08-13 |
2016-05-31 |
Круселл Холланд Б.В. |
Антитела против респираторного синцитиального вируса (pcb) и способы их применения
|
PL2470671T3
(pl)
|
2009-08-28 |
2015-05-29 |
Regeneron Pharma |
Przeciwciała antykinowe wiążące się z wieloma chemokinami CC
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
DK2488867T3
(da)
|
2009-10-14 |
2020-11-09 |
Janssen Biotech Inc |
Fremgangsmåder til affinitetsmodning af antistoffer
|
JP5756757B2
(ja)
|
2009-10-30 |
2015-07-29 |
東レ株式会社 |
C型肝炎ウイルス(hcv)に対して感染阻害活性を有する抗体及びその用途
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
CA2775373C
(fr)
|
2009-11-11 |
2019-10-29 |
Ganymed Pharmaceuticals Ag |
Anticorps specifiques pour la claudine 6 (cldn6)
|
EP2513148B1
(fr)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anticorps anti-her2 et leurs utilisations
|
DK2513146T3
(en)
|
2009-12-18 |
2017-07-31 |
Kancera Ab |
Antibodies against ROR1 capable of inducing cell death by CLL
|
EP2534257B1
(fr)
|
2010-02-12 |
2017-09-27 |
Oncomed Pharmaceuticals, Inc. |
Procédés d'identification et d'isolement de cellules exprimant un polypeptide
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
JP6039428B2
(ja)
|
2010-03-04 |
2016-12-07 |
シムフォゲン・アクティーゼルスカブSymphogen A/S |
抗her2抗体および組成物
|
CA2789071C
(fr)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Anticorps contre le csf-1r humain et leurs utilisations
|
US8468130B2
(en)
|
2010-04-02 |
2013-06-18 |
Skyfire Labs, Inc. |
Assisted hybrid mobile browser
|
WO2011125015A2
(fr)
|
2010-04-05 |
2011-10-13 |
Bar-Ilan University |
Polypeptides formant des pores pouvant être activés par une protéase
|
CA2799746C
(fr)
|
2010-05-17 |
2020-11-24 |
Sai Reddy |
Isolement rapide d'anticorps monoclonaux a partir d'animaux
|
AR081434A1
(es)
|
2010-06-10 |
2012-08-29 |
Lilly Co Eli |
Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
|
JP2012021943A
(ja)
|
2010-07-16 |
2012-02-02 |
National Cancer Center |
子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
|
US9163258B2
(en)
|
2010-07-23 |
2015-10-20 |
Fred Hutchinson Cancer Research Center |
Method for the treatment of obesity
|
CN103221429A
(zh)
|
2010-09-22 |
2013-07-24 |
诺沃—诺迪斯克有限公司 |
治疗因子viii抗体
|
EP3828205A1
(fr)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anticorps anti-ror1
|
BR112013010544A2
(pt)
|
2010-10-29 |
2016-08-02 |
Immunogen Inc |
moléculas de ligação ao egfr e imunoconjugados das mesmas
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
EP2455403A1
(fr)
|
2010-11-23 |
2012-05-23 |
Pierre Fabre Medicament |
Anticorps humanisés homogènes contre JAM-A qui inhibitent la prolifération
|
WO2012075158A1
(fr)
|
2010-12-01 |
2012-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps ror1 chimériques lapin/humain
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
JP2014506257A
(ja)
|
2011-01-06 |
2014-03-13 |
ダイアックス コーポレーション |
血漿カリクレイン結合タンパク質
|
ES2865068T3
(es)
|
2011-01-14 |
2021-10-14 |
Univ California |
Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012118693A1
(fr)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Méthodes de diagnostic d'infection par clostridium difficile
|
RU2592686C2
(ru)
|
2011-04-22 |
2016-07-27 |
ВАЙЕТ ЭлЭлСи |
Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения
|
CN107090043B
(zh)
|
2011-05-13 |
2021-12-07 |
加尼梅德药物公司 |
用于治疗表达密蛋白6之癌症的抗体
|
WO2013019730A1
(fr)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Anticorps dirigés contre la tip-1 et la grp78
|
EP2742067A4
(fr)
|
2011-08-12 |
2015-03-04 |
Omeros Corp |
Anticorps monoclonaux anti-fzd10 et leurs procédés d'utilisation
|
CN107722122B
(zh)
|
2011-09-23 |
2022-05-27 |
昂考梅德药品有限公司 |
Vegf/dll4结合剂及其应用
|
PT2766395T
(pt)
|
2011-10-13 |
2020-02-04 |
Domantis Ltd |
Polipéptidos de anticorpo que antagonizam cd40l
|
AU2012325804B2
(en)
|
2011-10-19 |
2017-09-07 |
Pharmacyclics Llc |
Use of inhibitors of Bruton's tyrosine kinase (Btk)
|
EP2589609A1
(fr)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Protéine se liant à un antigène et son utilisation pour l'adressage d'un produit pour le traitement du cancer
|
US20130131139A1
(en)
*
|
2011-11-17 |
2013-05-23 |
Oregon Health & Science University |
Ror1 as a gene target in acute lymphoblastic leukemia
|
EP2617319A1
(fr)
|
2012-01-17 |
2013-07-24 |
Braun GmbH |
Portion de tête et portion de poignée d'un dispositif de soins oraux
|
PL2818483T3
(pl)
|
2012-02-21 |
2018-01-31 |
Toray Industries |
Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
|
PL2818482T3
(pl)
|
2012-02-21 |
2019-11-29 |
Toray Industries |
Kompozycja farmaceutyczna do leczenia nowotworu
|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
EP2832856A4
(fr)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
Anticorps anti-lamp5 et son utilisation
|
CN104203281B
(zh)
|
2012-03-30 |
2019-07-26 |
东丽株式会社 |
胆囊癌的治疗和/或预防用药物组合物
|
EP2832365B1
(fr)
|
2012-03-30 |
2017-11-01 |
Toray Industries, Inc. |
Composition pharmaceutique pour le traitement et/ou la prévention du cancer du foie
|
EP2834271B1
(fr)
|
2012-04-03 |
2019-01-16 |
NovelMed Therapeutics, Inc. |
Anticorps anti-facteur bb humanisés et chimériques, et leurs utilisations
|
EP2844300B1
(fr)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anticorps anti-pmel17 et immunoconjugués
|
RU2014145633A
(ru)
|
2012-05-14 |
2016-07-10 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухолей
|
CN103421113B
(zh)
|
2012-05-22 |
2018-01-19 |
武汉华鑫康源生物医药有限公司 |
抗BLyS抗体
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
KR102312856B1
(ko)
|
2012-08-24 |
2021-10-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
CN103792364B
(zh)
|
2012-10-31 |
2016-06-08 |
张宝弘 |
用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
|
TW202206465A
(zh)
|
2012-11-14 |
2022-02-16 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
SG11201506650PA
(en)
|
2013-02-22 |
2015-09-29 |
Stemcentrx Inc |
Novel antibody conjugates and uses thereof
|
EP2789630A1
(fr)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Anticorps bispécifiques contre le CD3e et ROR1
|
JP2016518382A
(ja)
|
2013-04-26 |
2016-06-23 |
ピエール、ファーブル、メディカマン |
Axl抗体薬物複合体および癌の治療のためのその使用
|
MA38632B1
(fr)
|
2013-05-20 |
2019-10-31 |
Genentech Inc |
Anticorps anti-récepteur de transferrine et procédés d'utilisation
|
WO2015014376A1
(fr)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
|
EP3038659A4
(fr)
|
2013-08-28 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Conjugués anti-dll3 modifiés et procédés d'utilisation
|
MX2016005763A
(es)
|
2013-11-06 |
2016-08-19 |
Stemcentrx Inc |
Anticuerpos anti-claudina novedosos y metodos de uso.
|
RU2685914C1
(ru)
|
2013-12-11 |
2019-04-23 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
CA2931340A1
(fr)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anticorps et immunoconjugues anti-cd33
|
UA120753C2
(uk)
|
2013-12-17 |
2020-02-10 |
Дженентек, Інк. |
Біспецифічне антитіло до сd3 та cd20
|
US10183989B2
(en)
|
2013-12-24 |
2019-01-22 |
Novelmed Therapeutics, Inc. |
Methods of treating ocular diseases
|
US10308721B2
(en)
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
HUE050355T2
(hu)
|
2014-04-01 |
2020-12-28 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-6-specifikus immunreceptorok és T-sejt-epitópok
|
SG10202109752XA
(en)
*
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
CN106470708B
(zh)
|
2014-04-25 |
2019-12-31 |
皮埃尔法布雷医药公司 |
抗体-药物-缀合物和其用于治疗癌症的用途
|
CN109996544A
(zh)
|
2016-06-27 |
2019-07-09 |
加利福尼亚大学董事会 |
癌症治疗组合
|
CA3067829A1
(fr)
*
|
2017-06-23 |
2018-12-27 |
VelosBio Inc. |
Immunoconjugues d'anticorps ror1
|